# Anterix Inc.: financial statements, quarterly

ATEX · Nasdaq · CIK 1304492 · [Communication](/sectors/communication.md) · fiscal year ends Mar 31

Pages: [Overview](/companies/atex.md) · [Financials](/companies/atex/financials.md) · [Filings](/companies/atex/filings.md) · [Insiders](/companies/atex/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/atex/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1.1](/filings/0001304492-24-000121.md) | [1.3](/filings/0001304492-25-000024.md) | [1.3 d](/filings/0001304492-25-000056.md) | [1.5](/filings/0001304492-25-000096.md) | [1.6](/filings/0001304492-25-000109.md) | [1.6](/filings/0001304492-26-000010.md) | [1.4 d](/filings/0001304492-26-000027.md) | [1.4](/filings/0001304492-26-000046.md) | [1.6](/filings/0001304492-25-000109.md) | [1.6](/filings/0001304492-26-000010.md) | [2.0 d](/filings/0001304492-26-000027.md) | [2.0](/filings/0001304492-26-000046.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [1.1](/filings/0001304492-24-000121.md) | [1.2](/filings/0001304492-25-000024.md) | [2.2 d](/filings/0001304492-25-000056.md) | [1.8](/filings/0001304492-25-000096.md) | [1.8](/filings/0001304492-25-000109.md) | [1.1](/filings/0001304492-26-000010.md) | [1.1 d](/filings/0001304492-26-000027.md) | [1.1](/filings/0001304492-26-000046.md) | [1.2](/filings/0001304492-25-000109.md) | [1.1](/filings/0001304492-26-000010.md) | [1.3 d](/filings/0001304492-26-000027.md) | [1.2](/filings/0001304492-26-000046.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [2.3](/filings/0001304492-24-000121.md) | [1.0](/filings/0001304492-25-000024.md) | [(10.5) d](/filings/0001304492-25-000056.md) | [(15.0)](/filings/0001304492-25-000096.md) | [(13.1)](/filings/0001304492-25-000109.md) | [7.0](/filings/0001304492-26-000010.md) | [9.4 d](/filings/0001304492-26-000027.md) | [22.5](/filings/0001304492-26-000046.md) | [60.7](/filings/0001304492-25-000109.md) | [(9.1)](/filings/0001304492-26-000010.md) | [19.8 d](/filings/0001304492-26-000027.md) | [(0.2)](/filings/0001304492-26-000046.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.6](/filings/0001304492-24-000121.md) | [1.3](/filings/0001304492-25-000024.md) | [(0.1) d](/filings/0001304492-25-000056.md) | [1.2](/filings/0001304492-25-000096.md) | [0.2](/filings/0001304492-25-000109.md) | [(0.2)](/filings/0001304492-26-000010.md) | [0.7 d](/filings/0001304492-26-000027.md) | [(2.3)](/filings/0001304492-26-000046.md) | [7.5](/filings/0001304492-25-000109.md) | [(2.1)](/filings/0001304492-26-000010.md) | [1.9 d](/filings/0001304492-26-000027.md) | [0.4](/filings/0001304492-26-000046.md) |
| Net income | $m | [2.1](/filings/0001304492-24-000121.md) | [0.3](/filings/0001304492-25-000024.md) | [(9.4) d](/filings/0001304492-25-000056.md) | [(15.5)](/filings/0001304492-25-000096.md) | [(12.8)](/filings/0001304492-25-000109.md) | [7.7](/filings/0001304492-26-000010.md) | [9.2 d](/filings/0001304492-26-000027.md) | [25.2](/filings/0001304492-26-000046.md) | [53.5](/filings/0001304492-25-000109.md) | [(6.6)](/filings/0001304492-26-000010.md) | [18.5 d](/filings/0001304492-26-000027.md) | [0.2](/filings/0001304492-26-000046.md) |
| Diluted EPS | $ per share | [0.11](/filings/0001304492-24-000121.md) | [0.02](/filings/0001304492-25-000024.md) | not reported | [(0.84)](/filings/0001304492-25-000096.md) | [(0.69)](/filings/0001304492-25-000109.md) | [0.41](/filings/0001304492-26-000010.md) | not reported | [1.35](/filings/0001304492-26-000046.md) | [2.86](/filings/0001304492-25-000109.md) | [(0.35)](/filings/0001304492-26-000010.md) | not reported | [0.01](/filings/0001304492-26-000046.md) |
| Basic EPS | $ per share | [0.11](/filings/0001304492-24-000121.md) | [0.02](/filings/0001304492-25-000024.md) | not reported | [(0.84)](/filings/0001304492-25-000096.md) | [(0.69)](/filings/0001304492-25-000109.md) | [0.41](/filings/0001304492-26-000010.md) | not reported | [1.35](/filings/0001304492-26-000046.md) | [2.86](/filings/0001304492-25-000109.md) | [(0.35)](/filings/0001304492-26-000010.md) | not reported | [0.01](/filings/0001304492-26-000046.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: not reported
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [48.5](/filings/0001304492-24-000121.md) | [62.0](/filings/0001304492-25-000024.md) | [60.6](/filings/0001304492-26-000010.md) | [51.7](/filings/0001304492-25-000096.md) | [43.1](/filings/0001304492-25-000109.md) | [28.8](/filings/0001304492-26-000010.md) | [47.4](/filings/0001304492-26-000046.md) | [41.4](/filings/0001304492-26-000046.md) | [39.1](/filings/0001304492-25-000109.md) | [29.5](/filings/0001304492-26-000010.md) | [98.5](/filings/0001304492-26-000046.md) | [116](/filings/0001304492-26-000046.md) |
| Current assets | $m | [62.1](/filings/0001304492-23-000061.md) | [77.8](/filings/0001304492-24-000018.md) | [73.0](/filings/0001304492-25-000056.md) | [65.7](/filings/0001304492-24-000103.md) | [56.8](/filings/0001304492-24-000121.md) | [40.3](/filings/0001304492-25-000024.md) | [60.8](/filings/0001304492-26-000027.md) | [55.4](/filings/0001304492-25-000096.md) | [58.8](/filings/0001304492-25-000109.md) | [50.1](/filings/0001304492-26-000010.md) | [120](/filings/0001304492-26-000046.md) | [153](/filings/0001304492-26-000046.md) |
| Total assets | $m | [280](/filings/0001304492-23-000061.md) | [321](/filings/0001304492-24-000018.md) | [325](/filings/0001304492-25-000056.md) | [321](/filings/0001304492-24-000103.md) | [317](/filings/0001304492-24-000121.md) | [327](/filings/0001304492-25-000024.md) | [333](/filings/0001304492-26-000027.md) | [360](/filings/0001304492-25-000096.md) | [420](/filings/0001304492-25-000109.md) | [417](/filings/0001304492-26-000010.md) | [465](/filings/0001304492-26-000046.md) | [498](/filings/0001304492-26-000046.md) |
| Current liabilities | $m | [15.3](/filings/0001304492-23-000061.md) | [17.3](/filings/0001304492-24-000018.md) | [18.0](/filings/0001304492-25-000056.md) | [16.5](/filings/0001304492-24-000103.md) | [15.8](/filings/0001304492-24-000121.md) | [24.4](/filings/0001304492-25-000024.md) | [27.2](/filings/0001304492-26-000027.md) | [35.9](/filings/0001304492-25-000096.md) | [34.6](/filings/0001304492-25-000109.md) | [36.0](/filings/0001304492-26-000010.md) | [36.0](/filings/0001304492-26-000046.md) | [31.5](/filings/0001304492-26-000046.md) |
| Total liabilities | $m | [104](/filings/0001304492-23-000061.md) | [149](/filings/0001304492-24-000018.md) | [164](/filings/0001304492-25-000056.md) | [172](/filings/0001304492-24-000103.md) | [178](/filings/0001304492-24-000121.md) | [182](/filings/0001304492-25-000024.md) | [177](/filings/0001304492-26-000027.md) | [175](/filings/0001304492-25-000096.md) | [180](/filings/0001304492-25-000109.md) | [181](/filings/0001304492-26-000010.md) | [203](/filings/0001304492-26-000046.md) | [212](/filings/0001304492-26-000046.md) |
| Shareholders' equity | $m | [176](/filings/0001304492-25-000024.md) | [172](/filings/0001304492-25-000024.md) | [161](/filings/0001304492-26-000027.md) | [149](/filings/0001304492-25-000109.md) | [139](/filings/0001304492-26-000010.md) | [145](/filings/0001304492-26-000010.md) | [157](/filings/0001304492-26-000046.md) | [185](/filings/0001304492-26-000046.md) | [240](/filings/0001304492-26-000010.md) | [236](/filings/0001304492-26-000010.md) | [262](/filings/0001304492-26-000046.md) | [286](/filings/0001304492-26-000046.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q4 FY2024 (2024-03-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q4 FY2026 (2026-03-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [10.4 d](/filings/0001304492-24-000121.md) | [33.6 d](/filings/0001304492-25-000024.md) | [6.1 d](/filings/0001304492-25-000056.md) | [(2.4)](/filings/0001304492-25-000096.md) | [(2.6) d](/filings/0001304492-25-000109.md) | [(7.7) d](/filings/0001304492-26-000010.md) | [(16.6) d](/filings/0001304492-26-000027.md) | [(3.1)](/filings/0001304492-26-000046.md) | [1.4 d](/filings/0001304492-25-000109.md) | [(8.3) d](/filings/0001304492-26-000010.md) | [15.5 d](/filings/0001304492-26-000027.md) | [2.0](/filings/0001304492-26-000046.md) |
| Capital expenditure | $m | [0.2 d](/filings/0001304492-24-000121.md) | [0.1 d](/filings/0001304492-25-000024.md) | [0.0 d](/filings/0001304492-25-000056.md) | [0.0](/filings/0001304492-24-000103.md) | [0.0 d](/filings/0001304492-25-000109.md) | [0.0 d](/filings/0001304492-26-000010.md) | [0.0 d](/filings/0001304492-26-000027.md) | [0.0](/filings/0001304492-26-000046.md) | [0.0 d](/filings/0001304492-25-000109.md) | [0.0 d](/filings/0001304492-26-000010.md) | [0.0 d](/filings/0001304492-26-000027.md) | [0.0](/filings/0001304492-26-000046.md) |
| Share repurchases | $m | [10.7 d](/filings/0001304492-24-000121.md) | [8.0 d](/filings/0001304492-25-000024.md) | [6.0 d](/filings/0001304492-25-000056.md) | [2.0](/filings/0001304492-25-000096.md) | [0.0 d](/filings/0001304492-25-000109.md) | [4.4 d](/filings/0001304492-26-000010.md) | [2.0 d](/filings/0001304492-26-000027.md) | [0.0](/filings/0001304492-25-000096.md) | [1.0 d](/filings/0001304492-25-000109.md) | [0.0 d](/filings/0001304492-26-000010.md) | [0.0 d](/filings/0001304492-26-000027.md) | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q2 FY2023 (2022-09-30) | Q3 FY2023 (2022-12-31) | Q1 FY2024 (2023-06-30) | Q2 FY2024 (2023-09-30) | Q3 FY2024 (2023-12-31) | Q1 FY2025 (2024-06-30) | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q1 FY2027 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [19.0](/filings/0001304492-23-000061.md) | [18.9](/filings/0001304492-24-000018.md) | [19.0](/filings/0001304492-24-000103.md) | [19.1](/filings/0001304492-24-000121.md) | [18.9](/filings/0001304492-25-000024.md) | [18.5](/filings/0001304492-25-000096.md) | [18.6](/filings/0001304492-25-000109.md) | [18.8](/filings/0001304492-26-000010.md) | [18.7](/filings/0001304492-26-000046.md) | [18.7](/filings/0001304492-25-000109.md) | [18.7](/filings/0001304492-26-000010.md) | [19.6](/filings/0001304492-26-000046.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 19,609,786 at 2026-08-06, from the cover of the [10-Q filed 2026-08-11](/filings/0001304492-26-000046.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.